>
Switch to:

Allergy Therapeutics EBIT

: $4.9 Mil (TTM As of Jun. 2021)
View and export this data going back to 2004. Start your Free Trial

Allergy Therapeutics's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2021 was $-16.4 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2021 was $4.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Allergy Therapeutics's annualized ROC % for the quarter that ended in Jun. 2021 was -61.87%. Allergy Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2021 was -101.56%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Allergy Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2021 was 2.19%.


Allergy Therapeutics EBIT Historical Data

The historical data trend for Allergy Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.23 -8.74 5.70 10.73 5.82

Allergy Therapeutics Semi-Annual Data
Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.06 21.16 -9.48 21.26 -16.36

Allergy Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2021 adds up the semi-annually data reported by the company within the most recent 12 months, which was $4.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allergy Therapeutics  (OTCPK:AGYTF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Allergy Therapeutics's annualized ROC % for the quarter that ended in Jun. 2021 is calculated as:

ROC % (Q: Jun. 2021 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2020 ) + Invested Capital (Q: Jun. 2021 ))/ count )
=-32.953716690042 * ( 1 - -1.15% )/( (49.14247311828 + 58.604488078541)/ 2 )
=-33.332684431978/53.87348059841
=-61.87 %

where

Invested Capital(Q: Dec. 2020 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=133.0685483871 - 19.021505376344 - ( 64.904569892473 - max(0, 21.978494623656 - 92.950268817204+64.904569892473))
=49.14247311828

Invested Capital(Q: Jun. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=123.54698457223 - 9.3632538569425 - ( 56.483870967742 - max(0, 25.568022440393 - 81.147265077139+56.483870967742))
=58.604488078541

Note: The Operating Income data used here is two times the semi-annual (Jun. 2021) data.

2. Joel Greenblatt's definition of Return on Capital:

Allergy Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2021 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2021 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2020  Q: Jun. 2021
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-32.726507713885/( ( (26.213709677419 + max(9.0241935483871, 0)) + (27.653576437588 + max(1.5568022440393, 0)) )/ 2 )
=-32.726507713885/( ( 35.237903225806 + 29.210378681627 )/ 2 )
=-32.726507713885/32.224140953717
=-101.56 %

where Working Capital is:

Working Capital(Q: Dec. 2020 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(14.478494623656 + 13.564516129032 + 0.0026881720430083) - (19.021505376344 + 0 + 3.5527136788005E-15)
=9.0241935483871

Working Capital(Q: Jun. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.1514726507714 + 15.200561009818 + 5.3113604488078) - (9.3632538569425 + 0 + 13.743338008415)
=1.5568022440393

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2021) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Allergy Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2021 )
=5.8176718092567/265.096
=2.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allergy Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics Business Description

Allergy Therapeutics logo
Industry
Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergy with aluminium-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics Headlines

No Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)